Pharma Officials Insist That There Is 'Zero Evidence' That Patents Harm Access To Medicine

from the just-because-you-don't-look,-doesn't-mean-it's-not-there dept

We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we have remembered it, the larger they have been.

Thank you for reading this Techdirt post. With so many things competing for everyone’s attention these days, we really appreciate you giving us your time. We work hard every day to put quality content out there for our community. Techdirt is one of the few remaining truly independent media outlets. We do not have a giant corporation behind us, and we rely heavily on our community to support us, in an age when advertisers are increasingly uninterested in sponsoring small, independent sites — especially a site like ours that is unwilling to pull punches in its reporting and analysis. While other websites have resorted to paywalls, registration requirements, and increasingly annoying/intrusive advertising, we have always kept Techdirt open and available to anyone. But in order to continue doing so, we need your support. We offer a variety of ways for our readers to support us, from direct donations to special subscriptions and cool merchandise — and every little bit helps. Thank you.

–The Techdirt Team

Yesterday afternoon, the twitter feed for "LillyPad," which is Eli Lilly's "policy" blog and Twitter feed, excitedly tweeted out a quote from Stefan Oschmann, an executive at pharmaceutical competitor Merck, who was just elected as the new head of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) -- basically, the big pro-pharma lobbying group. The tweet is no longer there, because LillyPad deleted it, but here's a screenshot I took apparently seconds before it disappeared:As you can see, they're quoting Oschmann insisting that "there is zero evidence that intellectual property is a hindrance to access to medicines." Almost immediately, you can see that nearly all of the responses started pointing to... um... evidence of how patents are a hindrance to access to medicine. Here's an OxFam paper and a massive paper from Medicins San Frontieres (MSF) Access Campaign , which focuses specifically on improving access to life-saving medicines. Lots of other comments were just mocking the claim, with some asking if Lilly was going to post a correction.Perhaps recognizing just how ridiculous the whole thing looked, Lilly went with option "pretend it never happened" and deleted the tweet. What might have been better and more productive would have been to come out andthat the statement was bullshit and that there areabout how patents can hold back access to medicine. Anorganization might then try to kick off a discussion about the different issues and the tradeoffs, recognizing that patents clearly do harm access, butcould also create incentives that lead to new drug creation (this is the standard claim, anyway, though some are skeptical of that as well).But it appears that Eli Lilly (and IFPMA) have no interest in being intellectually honest or having such a discussion. No, they've decided to stick to the ridiculous and bogus corporate line that patents are all butterflies and roses, and do no harm at all. What a wasted opportunity -- even if it helped show the true colors of the current leadership of the pharmaceutical industry.And it's even more ridiculous that this all took place at an IFPMA event where "global health" was the key topic, and they talked about "inclusiveness" and "sustainability" along with transparency . But, in the end that's all clearly buzzwords and smoke screens, because when its new boss makes a stupid, clearly incorrect statement that shows what the industry is all about, the message gets hidden and there's no discussion or transparency at all. For shame.As for Dr. Oschmann, seeing as he's a long-term Merck exec, he'd do well to remember the words of George Merck, from nearly a century ago:It appears that sentiment has long since been beaten out of Merck.

Filed Under: access to medicine, patents, pharmaceuticals, stefan oschmann

Companies: eli lilly, ifpma, merck